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Abstract
Background: miRNAs are now recognized as key regulator elements in gene expression. Although they have been
associated with a number of human diseases, their implication in acute and chronic asthma and their association with lung
remodelling have never been thoroughly investigated.
Methodology/Principal Findings: In order to establish a miRNAs expression profile in lung tissue, mice were sensitized and
challenged with ovalbumin mimicking acute, intermediate and chronic human asthma. Levels of lung miRNAs were profiled
by microarray and in silico analyses were performed to identify potential mRNA targets and to point out signalling pathways
and biological processes regulated by miRNA-dependent mechanisms. Fifty-eight, 66 and 75 miRNAs were found to be
significantly modulated at short-, intermediate- and long-term challenge, respectively. Inverse correlation with the
expression of potential mRNA targets identified mmu-miR-146b, -223, -29b, -29c, -483, -574-5p, -672 and -690 as the best
candidates for an active implication in asthma pathogenesis. A functional validation assay was performed by cotransfecting
in human lung fibroblasts (WI26) synthetic miRNAs and engineered expression constructs containing the coding sequence
of luciferase upstream of the 39UTR of various potential mRNA targets. The bioinformatics analysis identified miRNA-linked
regulation of several signalling pathways, as matrix metalloproteinases, inflammatory response and TGF-b signalling, and
biological processes, including apoptosis and inflammation.
Conclusions/Significance: This study highlights that specific miRNAs are likely to be involved in asthma disease and could
represent a valuable resource both for biological makers identification and for unveiling mechanisms underlying the
pathogenesis of asthma.
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Introduction
Asthma is a complex chronic inflammatory disease characterized by
eosinophilic airway inflammation, reversible airway obstruction and
hyper-responsiveness. Moreover, asthma patients display a faster rate
of lung dysfunction than normal individuals related to a progressive
remodelling of airway walls [1,2]. Maj o rf e a t u r e so ft h i sr e m o d e l l i n g
process consist of epithelial damages, smooth muscle cell hyperplasia,
glandular hyperplasia and airway wall fibrosis including a thin collagen
layer deposition in the lamina reticularis of airway epithelium [2,3]. To
date, marketed asthma treatments are not sufficient to allow a
satisfactory level of control in every patient and are not effective
towards airways remodelling processes. Forthese reasons, identification
of new therapeutic targets and new biomarkers relevant for diagnosis
and prognosis evaluation are eagerly needed.
The evolution of the disease from acute inflammation to the
fibrotic process is driven by soluble factors, such as cytokines and
chemokines, and by cell-cell and cell-matrix interactions. An
abundant literature [4–10] shows that these regulatory signals
affect the level of transcription of several genes in leukocytes and in
specific lung cells. These transcriptomic studies led to the
identification of several potential new therapeutic targets but largely
failed to provide information about regulations operated at a post-
transcriptional level. MicroRNA-driven RNA interference is a
newly recognized and evolutionary conserved regulatory mecha-
nism. MiRNAs lead to the degradation and/or repression of
translation of specific mRNAs depending on the type of base-
pairing between the miRNA and its mRNA target [11]. In
mammals miRNA-dependent regulation mostly affects the transla-
tionprocess althoughmoderateandvariablelevelsofdegradation of
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16509thetarget arealsooften associated.Most interestingly,thisopensthe
possibility of inferring the existence of potent miRNA-driven
translational regulation from powerful and validated whole genome
transcriptomic studies. Taking into account that each mammal
genome contains several hundreds of miRNA [12], that the
complementarities between a miRNA and its target sequence are
usually not perfect, that a single miRNA may regulate the
translation/degradation of many mRNAs and that a single mRNA
can be affected by several different miRNAs, one can consider that
this type of investigation requires the use of powerful bioinformatics
tools able to analyse such complex pattern of interactions. Although
miRNA expression modulations have already been associated with
several human diseases [13–30], only few studies have explored the
role of miRNAs in non-tumoral lung diseases [31–38] and very little
is known about miRNAs expression profiles in the lung during the
course of asthma and asthma-induced airway remodelling.
In the present study, microarray analysis has been used to
determine miRNAs expression profiles in a mouse model of
asthma designed to investigate the development of both acute and
chronic responses to allergen. Moreover, in silico analysis and
comparison with the expression profile of mRNAs in the same
pathological state identified several genes and pathways that are
both involved in asthma and post-transcriptionally regulated by
miRNA-dependent processes. The best candidates were validated
by functional assays in cell culture.
Results and Discussion
Assessment of airway inflammation, sensitization and
hyperresponsiveness in mouse model of asthma
Mouse models of asthma are commonly considered as reliable
tools to study pathological mechanisms of the disease since these
animals, if adequately sensitized and exposed to allergens, develop
measurable airway hyperresponsiveness, airway inflammation, and
finally airway remodeling if the exposureto allergens persists [39–41].
The mouse model of asthma used in this study has previously
been characterized [4]. In comparison to control mice, animals
exposed to allergen showed an enhanced airway resistance after
increasing doses of metacholine as compared with the correspond-
ing PBS-exposed groups (Figure 1A). Percentages of goblet cells in
the bronchial epithelium (Figure 1B) and subepithelial collagen
deposition (Figure 1C) did increase over time in allergen-exposed
mice. Eosinophilic infiltration measured in bronchial walls was
significantly increased in each allergen-exposed group as com-
pared to controls while the eosinophils density in the bronchial
walls decreased over time (Figure 1D). Exposure to aerosolized
OVA induced a slight increase in differential cell numbers present
in the BAL fluids when compared to their PBS-exposed
counterparts (Table 1) which was expected from previous studies
[40,42] and largely resulted from eosinophilic representation.
Reproducibility of our mouse model of asthma induction was
further assessed by measuring in each individual mouse of the
current study. The relative abundance of 8 transcripts known from
a previous study [4] to be regulated at the 3 time-points of allergen
exposure (ST, IT and LT). The new data set is fully in agreement
with previous quantifications, except for Cdc2a at ST and LT
(Figure S1). All together these functional, cellular and transcrip-
tomic evaluations demonstrate the reproducibility of our models of
asthma from one experiment to another. These data allow us to
use the transcriptomic data from our previous study [4] to relate
mRNA targets with the miRNAs identified in this study. However,
the animal model of asthma used here can also bear per se some
limitations. For instance, allergen used in animals (ovalbumin) is
not a causative agent of human asthma in physiological conditions.
The animals are also anatomically different from human regarding
bronchial architecture since number of bronchial divisions is lower
in mice. Nevertheless, this model with its intrinsic limitations
allowed the investigators to reproduce all key features of asthmatic
airways as found in humans with an allergen-induced airway
inflammation and hyperresponsiveness as well as an allergen-
induced airway remodeling (figure 1A–D).
MiRNA expression changed in lungs during allergen
exposure
Lung total RNA was obtained from groups of mice exposed to
allergen(OVA)orcontrol(PBS)for1(ST),5(IT)and10(LT)weeks.
Microarray analysis indicated that 58, 66 and 75 mature miRNAs
out of 566 were significantly (p-value ,0.01) modulated at ST, IT
and LT, respectively (Table S1). For many of them, the fold
induction or repression in the OVA-treated mice was higher than
1.5 (20 at ST, 26 at IT and 67 at LT) (Table 2). Some miRNAs
underwent a significant modulation ($1.5-fold, p-value ,0.01) at
two time-points but only one, mmu-miR-146b, was consistently
upregulated at the three investigated time-points (Table 3).
Modulated miRNAs after short term (ST) and
intermediate term (IT) exposure to allergen. Mmu-miR-
690 was downregulated at ST and IT but was no longer
modulated at LT. In the literature, this miRNA was only
reported to be significantly downregulated in pancreatic b cells
after treatment with high glucose [43]. The second miRNA
significantly regulated, mmu-miR-223, was previously shown to
play a significant role in pulmonary function alteration by
exposition to cigarette smoke [31] or to LPS [33]. It is also
known to be involved in hematopoietic development [44–47], to
be expressed by PBMC [48] and neutrophils [33] and to be
implicated in malignancies such as ovarian cancer [49],
hepatocellular carcinoma [50] and bladder cancer [51].
Modulated miRNAs after short term (ST) and long term
(LT) exposure to allergen. Three miRNAs, mmu-miR-672,
-574-5p and -483 were downregulated at ST and upregulated at
LT. To our knowledge, only miR-483 has been previously
associated to a specific disease or a physiological state and was
found to be significantly correlated with cardiac hypertrophy [52].
Modulated miRNAs after intermediate term (IT) and long
term (LT) exposure to allergen. Mmu-miR-423-5p, -455,
-466f-3p, -466g, -467a* and -467b* were consistently upregulated at
IT and LT. Among these miRNAs, miR-455 has been reported to be
implicated in brown adipocyte differentiation [53], while the functions
or targets of the others are not determined yet. These miRNAs could
become interesting markers of late phases of asthma development as
they are significantly upregulated. By contrast to these six miRNAs,
mmu-miR-29c is downregulated at these two time-points. MiR-29 has
been reported to be involved in various human cancers [54-57] and in
tumour suppression by targeting the T-cell leukemia/lymphoma 1
(Tcl1) oncogene mRNA [54], by reverting DNA methylation by
targeting DNA methyltransferases 3A (Dnmt3a) and 3B (Dnmt3b)
mRNA [58] and by regulating p53 pathway through Cdc42 and p85a
[59]. Moreover, its targets mRNAs encoding extracellular matrix
proteins have been associated with cell migration and metastasis such
as Col3a1, Col4a1, Col15a1, Lamc1 [60]. MiR-29 regulates also
muscle cell differentiation probably, in part, under a feed-back control
of NF-kB-YY1 pathway [61].
Modulated miRNAs after short term (ST), intermediate
term (IT) and long term (LT) exposure to allergen. Mmu-
miR-146b was the only miRNA consistently upregulated during
the entire time-course of the experiment. MiR-146b is expressed
by leukocytes and its function is clearly associated with
inflammation and innate immunity [33,62]. Taganov et al. [63]
MiRNA in Mice Models of Asthma
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cytokine signalling, rather than totally abrogating the signal, in
response to microbial components and proinflammatory cytokines.
Moreover, this miRNA acts as a negative regulator of NF-kB
activity in a human breast cancer cell line [64].
Microarray validation
Before considering further the potential implication of the
regulation affecting the expression of several miRNAs, micro-
arrays data, that were obtained by hybridization of RNA pools,
were validated by RT-qPCR quantification for each individual
Table 1. Differential cell counts in BAL fluids.
ST IT LT
PBS OVA PBS OVA PBS OVA
Epithelial cells (610
4/ml) 4.960.8 4.761.9 1.860.8 3.560.7 1.560.2 3.860.5
Eosinophils (610
4/ml) 5.261.7 75.0630.7 1.660.4 8.161.5 2.360.4 11.361.8
Lymphocytes (610
4/ml) 0.260.1 0.560.1 0.160.0 0.260.1 0.260.1 0.560.1
Macrophages (610
4/ml) 36.966.0 22.166.1 17.661.1 22.963.6 26.963.1 21.561.9
Neutrophils (610
4/ml) 0.160.0 2.160.1 0.160.0 0.660.2 0.260.1 1.160.2
Cellular composition of BAL fluid and absolute cell counts performed 24 hours after the last allergen or PBS exposure. ST, IT, LT: short, intermediate and long-term
treatments, respectively.
doi:10.1371/journal.pone.0016509.t001
Figure 1. Assessment of airway inflammation, sensitization and hyperresponsiveness. Assessment of airway responsiveness to
metacholine (Panel A), of glandular hyperplasia as percentage of goblet cells per total epithelial cells (Panel B), of peribronchial collagen deposition
(Panel C) and of eosinophils accumulation (Panel D) in randomly selected bronchi in PBS and OVA-treated groups of mice at short-term (ST),
intermediate-term (IT) and long-term (LT) sensitization and exposure protocols. Mean scores were measured as described in [4]. Results are expressed
as means 6 SE and the comparison between groups was performed using Mann-Whitney U test (* p-value ,0.05; ** p-value ,0.005; *** p-value
,0.001; N.S.: not significant).
doi:10.1371/journal.pone.0016509.g001
MiRNA in Mice Models of Asthma
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several miRNAs undergoing regulation at, at least, two time-points
(such as mmu-miR-146b, -29c…) and for miRNAs selected on the
basis of their abundancy (such as mmu-let-7b, mmu-miR-21,
-145…), the magnitude of the observed regulations (such as mmu-
miR-574-5p, -672…) and the potential significance of their mRNA
targets (see below). In some cases, PCR amplifications were
perturbed by several unspecific products preventing an accurate
Table 2. List of significantly modulated mature miRNAs
($1.5-fold, p-value ,0.01) and their respective fold induction
at each time-point.
UPREGULATION DOWNREGULATION
MIRNA FI MIRNA FI
ST
mmu-miR-712* 5.24 mmu-miR-187 0.66
mmu-miR-122 5.08 mmu-miR-497 0.49
mmu-miR-181d 2.51 mmu-miR-690 0.49
mmu-miR-106a 2.28 mmu-miR-1 0.46
mmu-miR-223 1.99 mmu-miR-483 0.39
mmu-miR-146b 1.91 mmu-miR-574-5p 0.37
mmu-miR-181b 1.91 mmu-miR-203 0.35
mmu-miR-689 1.90 mmu-miR-672 0.35
mmu-miR-20b 1.88 mmu-miR-805 0.28
mmu-miR-451 1.60
mmu-miR-100 1.52
IT
mmu-miR-155 4.48 mmu-miR-322 0.66
mmu-miR-467b* 2.97 mmu-miR-429 0.66
mmu-miR-467a* 2.79 mmu-miR-199a-3p 0.63
mmu-miR-466g 2.64 mmu-miR-152 0.63
mmu-miR-466f-3p 2.23 mmu-miR-29c 0.62
mmu-miR-455 2.03 mmu-miR-218 0.62
mmu-miR-150 1.80 mmu-miR-200a 0.59
mmu-miR-423-5p 1.69 mmu-miR-10a 0.59
mmu-miR-146b 1.55 mmu-miR-10b 0.53
mmu-miR-375 1.52 mmu-miR-29b 0.52
mmu-miR-101a 0.36
mmu-miR-223 0.32
mmu-miR-19b 0.31
mmu-miR-690 0.24
mmu-miR-450a-5p 0.19
mmu-miR-126-5p 0.14
LT
mmu-miR-705 119.30 mmu-miR-200b 0.61
mmu-miR-188-5p 117.39 mmu-miR-92a 0.60
mmu-miR-483 115.80 mmu-miR-30c 0.59
mmu-miR-669c 115.25 mmu-miR-27a 0.53
mmu-miR-568 96.03 mmu-let-7e 0.50
mmu-miR-467b* 48.35 mmu-miR-21 0.47
mmu-miR-691 42.50 mmu-miR-25 0.46
mmu-miR-671-5p 39.54 mmu-miR-30b 0.44
mmu-miR-467a* 39.02 mmu-miR-23b 0.41
mmu-miR-485* 33.41 mmu-miR-23a 0.38
mmu-miR-744 29.56 mmu-miR-26b 0.31
mmu-miR-466f-3p 22.69 mmu-miR-98 0.20
mmu-miR-685 19.58 mmu-miR-15a 0.19
mmu-miR-709 18.98 mmu-miR-29c 0.11
mmu-miR-467e* 18.51
mmu-miR-466c-5p 17.07
mmu-miR-466g 16.19
Table 2. Cont.
UPREGULATION DOWNREGULATION
MIRNA FI MIRNA FI
mmu-miR-574-3p 15.99
mmu-miR-574-5p 13.18
mmu-miR-667 13.13
mmu-miR-713 11.83
mmu-let-7d* 11.72
mmu-miR-762 11.22
mmu-miR-466d-3p 9.95
mmu-miR-466b-3-3p 9.89
mmu-miR-466f-5p 9.50
mmu-miR-297a* 9.21
mmu-miR-468 8.99
mmu-miR-466a-3p 8.48
mmu-miR-197 8.06
mmu-miR-455 7.51
mmu-miR-877* 6.41
mmu-miR-297a 6.38
mmu-miR-15a* 6.14
mmu-miR-207 6.03
mmu-miR-346 5.84
mmu-miR-466h 5.54
mmu-miR-206 5.48
mmu-miR-328 5.38
mmu-miR-672 5.30
mmu-miR-214 5.29
mmu-miR-320 4.52
mmu-miR-34c* 4.26
mmu-miR-423-5p 4.04
mmu-miR-674 3.84
mmu-miR-151-3p 3.18
mmu-miR-143 2.86
mmu-miR-146b 2.69
mmu-miR-720 2.69
mmu-miR-146a 2.09
mmu-miR-99b 2.03
mmu-miR-125b-5p 1.88
mmu-miR-145 1.75
mmu-miR-30d 1.64
mmu-miR-191 1.59
ST, IT, LT: short, intermediate and long-term treatments, respectively; FI: fold
induction.
doi:10.1371/journal.pone.0016509.t002
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low level of some miRNAs and strongly related to the short size of
mature miRNA preventing the design of highly specific primers. In
order to overcome this technical problem, LNA-containing
primers were designed to quantify these hard to amplify miRNAs
(mmu-miR-146b, -29b and -29c). Quantitative RT-PCR was
performed at the three time-points for 14 miRNAs, representing a
total of 42 calculations of the OVA/PBS ratios based on individual
mice measurements. Among these data, 40 out of 42 (95%) gave
results and trends similar to those obtained by microarray
profiling, except for mmu-miR-29c at ST and LT (Figure 2),
although the magnitude of the observed regulation was not always
identical (mmu-miR-455 at LT and mmu-miR-450a at IT).
Besides problems related to PCR amplification as experienced
with mmu-miR-29c, another potential explanation for the
differences observed between the two quantification procedures
could be related to the relative abundance of precursor miRNA
(pre-miRNA) that are characterized by the persistence of a stem-
loop structure. Depending upon their sequence and stability, these
stem-loops are indeed expected to affect differently the efficiencies
of the RT-PCR amplifications and the hybridization with probes
immobilized on microarrays. As a result, differences in micro-
arrays and RT-PCR data for a specific miRNA may be related to
modifications of the level of its pre-miRNA, thus to the regulation
of its transcription.
All together, these data demonstrate that microarray analysis is
reliable and allows to detect changes in the level of expression of a
large panel of miRNAs, providing a unique opportunity to
investigate the role of miRNA-based RNA interference during the
course of asthma.
Several miRNAs were expected to participate in the
regulation of biological processes during the course of
asthma development
Knowing that miRNA can induce a significant degradation of
its target and assuming also that evolution progressively selected
inverse regulation of expression of mRNAs and their specific
miRNAs, we determined (MicroCosm Target algorithm) for each
miRNA its potential target(s) and the regulatory pathways that are
expected to be regulated (Tables S2, S3 and S4). Among these
results, we focused on predicted pairs of miRNAs and mRNAs
that are inversely regulated at 2 time-points with a p-value ,0.05
(Table 4). The potential targets of mmu-miR-146b, the only
miRNA being significantly upregulated throughout the experi-
ment, were also identified (Table 5). Collectively, these 7 selected
miRNAs are expected to participate in the regulation of several
biological processes involved in asthma as illustrated in Figure 3.
Functional correlation between the expression of miRNAs
and some of their potential targets. AsshowninTables4 and
5, modulation of some miRNAs could be involved in the
pathogenesis of asthma by regulating genes at acute and/or
chronic stages of the disease. We selected 8 miRNAs (those
described in Tables 4 and 5 and mmu-miR-29b) and, at least, 2 of
their potential targets for functional testing in vitro (Figures 4 and 5).
In this assay, cells from lung origin were cotransfected with
synthetic miRNA mimic or non-functional small RNA control and
expression vectors containing the coding sequence of luciferase
cloned upstream of either an irrelevant control 39UTR or the
39UTR of the respective potential mRNA target. In this
experimental set up, the efficiency of the miRNA-dependent
regulation was directly proportional to the decrease in luciferase
activity used as a reporter.
For miR-146b, which was up-regulated at the 3 time-points,
and for miR-29b and -29c, which are thought to be regulators of
extracellular matrix remodelling and are downregulates at IT and
LT, increasing concentrations were tested to evaluate the
sensitivity and the specificity of the assays (Figure 4).
Despite their close sequence similarity, miR-29 members
showed different inhibitory patterns. MiR-29b mimic reduced
efficiently and dose-dependently the luciferase activity from
constructs containing the 39UTRs of mouse Mmp-15 and Mmp-
24 while miR-29c had only a limited effect at high concentration
on Mmp-24 39UTR (Figure 4A, B). Since the sequence of miR-
29b and -29c are identical in human and mouse, their efficiencies
were also evaluated using the 39UTRs of human Mmp-15 and
Mmp-24. Similar regulations were observed using human and
mouse 39UTRs, which confirm both the specificity of the
inhibitions and the relevance of our findings in the context of
human asthma.
Among the 17 others miRNA-mRNA pairs that were evaluated
(Figure 4E-H and Figure 5), significant inhibition was observed in
10 experimental conditions (miR-29c and Ctsk; miR-146b and
Scube2; miR-483 and Nola2 or Ube2c; miR-672 and Phb2; miR-
223 and Il6 or Lpin2 or Arid4b; miR-690 Fst or Ctse). All together
these validation analyses indicate that 64% (16/25) of the in silico
predicted regulations are effective while inhibitions were also
observed in the 9 remaining cases but were too low to reach
statistical significance. Although optimization of the experimental
design (timing for sample collection, transfection conditions, target
concentration…) would have probably led to the confirmation of
other miRNA-mRNA regulatory pairs, these experiments were
not further continued since the aim of these functional assays was
only to validate the in silico predictions before addressing the
potential roles of miRNAs during asthma.
Identification of biological processes regulated by
miRNAs. Genes involved in transcriptional regulation are
modulated at each time-point in our experimental model [4].
Four of selected miRNAs (Tables 4 and 5) displayed a clear
correlation with this biological process at 2 or 3 time-points. The
expression of mmu-miR-483 and -672 was downregulated at ST
Table 3. miRNAs undergoing a significant modulation ($ 1.5-
fold, p-value ,0.01) determined by microarray analysis at, at
least, 2 time-points.
FOLD INDUCTION
ST IT LT
mmu-miR-690 0.49 0.24 N.C.
mmu-miR-223 1.99 0.32 N.C.
mmu-miR-672 0.35 N.C. 5.31
mmu-miR-574-5p 0.37 N.C. 13.18
mmu-miR-483 0.39 N.C. 116.16
mmu-miR-29c N.C. 0.62 0.11
mmu-miR-423-5p N.C. 1.69 4.03
mmu-miR-455 N.C. 2.03 7.52
mmu-miR-466f-3p N.C. 2.23 22.63
mmu-miR-466g N.C. 2.64 16.22
mmu-miR-467a* N.C. 2.79 39.12
mmu-miR-467b* N.C. 2.97 48.50
mmu-miR-146b 1.91 1.55 2.69
ST, IT, LT: short, intermediate and long-term treatments, respectively; N.C.: no
change between PBS and OVA.
doi:10.1371/journal.pone.0016509.t003
MiRNA in Mice Models of Asthma
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miR-223 and -146b were increased. Their putative targets in this
biological process embrace direct transcription initiator (TOP2A,
topoisomerase II a), transcription factors (ZFP451, BTF3, KLF13
and TCFCP2L1), transcription coactivators (LPIN2) or
corepressors (FOXP4, GMNN, PHB2) and proteins playing
roles in functional organization of chromosome structure
through chromatin remodeling (ARID4B).
We also observed that the mRNA potentially targeted by mmu-
miR-223 (Arid4b, Lpin2, see Figure 5) and mmu-miR-146b
(Zfp451, Klf13 and Tcfcp2l1) did undergo a downregulation at
ST. This effect could be reinforced by the downregulation of
mmu-miR-672, which potentially targets PHB2, a factor that
restrains estrogen action and its activating pathway [65] and by
repression of mmu-miR-483 that could be responsible for the
observed upregulation of GMNN, an inhibitor of HOX-
dependent transcriptional activity [66]. However, topoisomerase
II a (Top2a) mRNA, which appears to be inversely correlated to
mmu-miR-672 expression, was significantly upregulated at ST and
downregulated at LT. An inversion in the pattern of transcription-
related mRNA-miRNA modulations was shown at LT exposure to
allergens. From these findings, it can be speculated that the
potential role of miRNAs in the modulation of transcription
mechanisms would mostly consist in a fine-tuning process rather
than striking regulations.
Cell cycle. MiRNA targeting genes regulating cell cycle are
clearly downregulated at ST, not affected at IT and upregulated at
LT. GMNN, which negatively regulates cell cycle, and MKI67,
which is an endogenous marker of proliferative cells, are putative
targets of mmu-miR-483. The expression of CCNB1 (cyclin B1)
that activates CDK1 driving G2/M-phase progression [67], of
CDCA8 (borealin) that is required for the proper segregation of
chromosomes during mitosis [68] and of NUSAP1 that is
selectively expressed in proliferative cells and is a positive
regulator of mitosis by acting on microtubules organization [69]
were significantly inversely correlated to mmu-miR-574-5p
Figure 2. Validation of microarray data by real-time RT-qPCR. Comparison of miRNA level regulation as determined by microarray
hybridization (several probes per target) performed on pooled total RNA and by RT-qPCR performed on total RNA of each individual mice. Results are
expressed as means 6 SD. The value ‘‘1’’ is arbitrarily given when no change is observed. ST, IT, LT: short, intermediate and long-term treatments,
respectively. FI: fold induction.
doi:10.1371/journal.pone.0016509.g002
MiRNA in Mice Models of Asthma
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e16509Table 4. Prediction of the mRNA targets for miRNA regulated at 2 time-points in the mouse model of asthma.
MMU-MIRNA TARGETED MRNA MICROCOSM TARGETS ASSOCIATED BIOLOGICAL PROCESS
FI FI P-VALUE
miR-223 1.99
ST ARID4B 0.64
ST 0.0009 Transcription regulation
0.32
IT ARID4B 19.70
IT
CFLAR 0.66
ST 0.0068 Apoptosis
CFLAR 4.44
IT
IL6 0.47
ST 0.0110 Inflammation
IL6 2.00
IT
LPIN2 0.57
ST 0.0050 Transcription regulation
LPIN2 2.14
IT
miR-690 0.49
ST 2010001M09RIK 6.06
ST 0.0283 Apoptosis
0.24
IT 2010001M09RIK 2.00
IT
CDCA8 3.03
ST 0.0472 Cell cycle
CDCA8 1.87
IT
CTSE 1.57
ST 0.0092 Immune response
CTSE 2.73
IT
FST 1.87
ST 0.0008 Cell differentiation
FST 2.64
IT
miR-29c 0.62
IT COL6A2 1.80
IT 0.0000 Extracellular matrix
0.11
LT COL6A2 1.87
LT
CTSK 1.87
IT 0.0007 Protein metabolism
CTSK 1.80
LT
METRNL 2.30
IT 0.0041 Cell differentiation
METRNL 1.62
LT
miR-483 0.39
ST GMNN 1.62
ST 0.0455 Transcription regulation
116.16
LT GMNN 0.55
LT
MKI67 2.64
ST 0.00147 Cell division
MKI67 0.45
LT
NOLA2 1.74
ST 0.0300 Ribosome biogenesis
NOLA2 0.55
LT
UBE2C 2.46
ST 0.0012 Protein metabolism
UBE2C 0.39
LT
miR-574-5p 0.37
ST CCNB1 4.76
ST 0.0339 Cell cycle
13.18
LT CCNB1 0.10
LT
CDCA8 3.03
ST 0.0006 Cell cycle
CDCA8 0.35
LT
DERA 1.57
ST 0.0058 Nucleotide synthesis
DERA 0.66
LT
NUSAP1 2.00
ST 0.0477 Cell cycle
NUSAP1 0.28
LT
miR-672 0.35
ST CD3G 1.74
ST 0.0054 Immune response
5.31
LT CD3G 0.32
LT
PHB2 1.68
ST 0.0042 Transcription regulation
PHB2 0.66
LT
PPP1R14B 1.74
ST 0.0069 Cell signalling
PPP1R14B 0.62
LT
TOP2A 2.46
ST 0.0037 Transcription regulation
TOP2A 0.29
LT
The rationale for calculation (MicroCosm Target algorithm) is based on sequence complementarity between miRNA and the 39UTR of its potential target, and on the
inverse correlation of their regulation. The associated biological processes are also indicated.
ST, IT, LT: short, intermediate and long-term treatments, respectively. FI: fold induction.
doi:10.1371/journal.pone.0016509.t004
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proliferation predominates at the early stages of asthma
development rather than in the late stage and might probably
partly be under miRNA control, especially through mmu-miR-
574-5p regulation.
Protein metabolism. Inverse correlations were also
observed between miRNAs and genes involved in protein
metabolism. As discussed further in the Inflammatory Response
Pathway section, mmu-miR-29 appears to be a miRNA family
displaying a protective role against fibrosis. Mmu-miR-29c
decrease could lead to the upregulation of CTSK (cathepsin K,
see Figure 4F) at the intermediate and the late stages of asthma
progression. CTSK is involved in lung matrix homeostasis by
degrading extracellular matrix proteins before their secretion,
therefore preventing excessive matrix deposition [70].
Ubiquitination is a step leading to protein degradation by the
proteasome. Transcriptional downregulation was observed for
some factors contributing to this process (UBE2C, UBE2D2 and
UBR1), especially at the LT time-point. A statistically significant
inverse correlation has been observed with increased mmu-miR-
146b and -483 expressions. According to our data, protein
production is repressed during the first phases of asthma
development and then increases concomitantly with tissue
remodeling at the late stages of the disease. These modulations
could result from the simultaneous regulation of the levels mmu-
miR-483 (see Figure 5), -672 and -146b.
Apoptosis, immunity, inflammation and cell signall-
ing. In silico analysis have also pointed significant correlations
between miRNA (mmu-miR-146b, -223 and -690) and
modulations of mRNAs related to apoptosis processes. Induction
of apoptosis in inflammatory cells, including eosinophils, might
have a beneficial effect on airway hyperresponsiveness observed at
ST [71] while its inhibition at IT might lead to the development of
allergic disease [72]. Regulation of apoptosis by miRNAs is
expected to occur via NF-kB pathway by inducing the degradation
or inhibiting the translation of apoptosis-related mRNA as already
described for mmu-miR-146b [63]. In our model, CFLAR, an
NF-kB-inducible anti-apoptotic protein which inhibits caspase 8-
mediated apoptosis, is a putative target of mmu-miR-146b and -
223. The upregulation of these two miRNAs at ST should
therefore induce apoptotic mechanisms in inflammatory cells. This
hypothesis is further reinforced by the demonstration that mmu-
miR-146b inhibits the expression of CARD10 (see Figure 4H), a
molecular scaffold for the assembly of a BCL10 signalling complex
that activates NF-kB [73].
MiR-146 is also associated with inflammation and innate
immune responses where it regulates the response to a variety of
microbial components and proinflammatory cytokines [63]. In our
ST protocol, upregulation of mmu-miR-146b and -223 is
predicted to repress SCUBE2 and IL-6, factors that are under
the control of IL-1b and TNF-a [74,75], probably through NF-kB
activation.
The immune response, clearly stimulated by OVA in the early
phase of asthma development [4], is mediated by CD4
+ T helper
cells, eosinophils, neutrophils, macrophages, and IgE antibodies.
The increased expression of CTSE (cathepsin E) at ST [4]
stimulates the generation of antigenic epitopes from OVA
(Figure 6) [76]. Similarly, an overexpression of CD3G, a protein
forming a complex with TCR, favour the activation process.
Signalling upon TCR stimulated by MHC presented antigen
induces IL-13 production, antigen-specific Th2 response and
expression of anti-apoptotic genes through NF-kB translocation
[77]. A co-stimulatory pathway of regulation involves the cross-
link of receptors on T cells with their corresponding ligand(s), such
as TNFRSF9 with TNFSF9 (Figure 6). These different pathways
are under direct control of several miRNAs. Mmu-miR-690 and-
672, that were repressed at ST, are potential inhibitors of CTSE
and CD3G production meaning that their downregulation could
increase the activation of T cells. Similarly, the continuous
overexpression of mmu-miR-146b should reduce the synthesis of
CLEC4D and TNFSF9. The stimulation of TNFRSF9 in vivo has
been shown to inhibit allergic asthma by decreasing IgE
production [78] and regulation of the B cell response [79,80]
and to fine-tune the Th1/Th2 balance [77]. The inhibition of
Table 5. Predicted mRNA targets of mmu-miR-146b at the 3
time-points.
TARGET MRNA FI
ASSOCIATED BIOLOGICAL
PROCESS
MICROCOSM
TARGETS
P-VALUE
ST (mmu-miR-146b FI =1.91)
ALS2CL 0.59 GTPase activator activity 0.0035
AP4S1 0.57 Vesicle mediated transport 0.0028
APLP2 0.48 ECM organization 0.0097
CARD10 0.55 Apoptosis/NF-kB activation 0.0003
CFLAR 0.66 Apoptosis/NF-kB activation 0.0371
CLEC4D 0.39 Immune response 0.0016
GPR116 0.57 Cell signalling 0.0038
KLF13 0.66 Transcription regulation 0.0436
NCOA4 0.64 Nuclear receptor activator 0.0191
NUMB 0.62 Cell signalling 0.0089
RASIP1 0.66 Angiogenesis 0.0000
SCUBE2 0.52 Inflammation 0.0002
TCFCP2L1 0.57 Transcription regulation 0.0391
TNFSF9 0.59 Immune response 0.0021
UBR1 0.66 Protein metabolism 0.0001
UTRN 0.64 Cell signalling 0.0095
ZFP451 0.57 Transcription regulation 0.0003
IT (mmu-miR-146b FI =1.56)
BAIAP2L1 0.66 Cell signalling 0.0004
FOXP4 0.52 Transcription regulation 0.0134
HIST2H3C2 0.52 Nucleosome assembly 0.0371
PKP2 0.62 Cell interaction 0.0010
ZNHIT1 0.64 Unknown 0.0084
LT (mmu-miR-146b FI =2.69)
BTF3 0.64 Transcription regulation 0.0367
CDCA3 0.44 Cell cycle 0.0300
DTYMK 0.62 Nucleotide biosynthesis 0.0052
HMGCS1 0.66 Lipidic metabolism 0.0069
HORMAD1 0.47 Cell cycle 0.0046
KIF22 0.29 Microtubules 0.0036
MGEA6 0.55 Unknown 0.0230
RPS9 0.62 Protein metabolism 0.0001
UBE2D2 0.62 Protein metabolism 0.0418
WDR12 0.59 Cell signalling 0.0261
Mmu-miR-146b is upregulated and predicted targeted mRNA are
downregulated at each time-point. ST, IT, LT: short, intermediate and long-term
treatments, respectively. FI: fold induction.
doi:10.1371/journal.pone.0016509.t005
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function in the evolution of the disease.
Another aspect of cell function appeared to be modulated by
mmu-miR-146b. NUMB expression is inhibited by miR-146a in
various cell lines [81]. NOTCH and NUMB controls the
proliferative/differentiation balance in development and homeo-
stasis. An increased degradation of NUMB, that antagonizes the cell
surface receptor NOTCH, leads to uncontrolled cell proliferation in
human mammary gland tumors [82]. Hyperplasia is also a
characteristic of remodelling of airway walls and concerns epithelial
cells, smooth muscle cells, fibroblasts and goblet cells. A decrease in
NUMB at ST should result in substantial increase of cell
proliferation. In the LT protocol, a downregulation of WDR12,
another putative target of mmu-miR-146b, was also observed. This
factor is involved in differentiation processes related to NOTCH
signalling [83]. Therefore, mmu-miR-146b probably controls some
aspect of cell proliferation and may participate in the development
of subepithelial fibrosis in asthma, by regulating NUMB and
WDR12 expression in the NOTCH signalling pathway.
MiRNAs modulation in different mice models of asthma
was significantly associated with four signalling
pathways
A large scale unbiased approach to determine the significance of
the observed regulations of miRNA expression was also used. At
each time-point, a set of predicted mRNA targets was identified
for each miRNA significantly up- or downregulated above 1.5
fold. The use of a cut-off threshold of 1.5 on the fold-change is not
uncommon in the context of miRNA profiling studies [84-86].
Since a single miRNA has several targets, moderate modifications
of its expression may have deep impact at a cellular level.
Moreover for studies profiling miRNA in complex tissues, such as
lung in this study, a cut-off of 1.5 is more appropriate to identify
regulations affecting only subpopulation of cells and not the entire
organ. Based on the known functions of the protein encoded by
these mRNA, pathways of regulation affecting behaviour and
partly controlled by miRNAs can be identified. In order to further
strengthen the analysis, two different databases were used. Target
Figure 3. Potential regulation performed by miRNAs during the development of allergen-induced asthma. This in silico prediction is
based on significant inverse correlation between mRNA and miRNA modulation of expression as detailed in tables 4 and 5. ST, IT, LT: short,
intermediate and long-term treatments, respectively. The observed up- ( ) and down- ( ) regulations of the expression of the selected miRNAs are
reported.
doi:10.1371/journal.pone.0016509.g003
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optimal sequence complementarity between a set of mature
miRNAs and a given mRNA using an algorithm reflecting the
weight of each base position and allowing mismatches at the 59
end of miRNA [87]. Target prediction by TargetScan database is
established on sequence complementarity to target sites with
emphasis on perfect base-pairing in the seed region and on
sequence conservation among species [88].
Sixteen pathways at ST, 25 at IT and 19 at LT were selected
with a combined p-value ,0.05 (Tables S5, S6 and S7) with
MicroCosm Targets database and 16 pathways at ST, 21 at IT
and 32 at LT were selected with a combined p-value ,0.05 (Tables
S8, S9 and S10) with TargetScan database. The comparison of
these data highlighted four common pathways that are modulated
at the three time-points (Figures 7 and 8). Matching results from
the two algorithms allowed us to select signalling pathways
strongly involved in the development of asthma. Some interactions
between modulated miRNAs and their potential targets are
discussed below.
Matrix Metalloproteinases Pathway. Matrix Metallopro-
teinases (MMPs) Pathway (WP441) was the most significantly
modified by the miRNA modulation at the three time-points (p-
value #0.01), which confirms our previous transcriptomic analysis
[4]. MMPs and their inhibitors (tissue inhibitors of matrix
metalloproteinases, TIMPs) contribute to the pathogenesis of
asthma by regulating the cleavage of peptidic mediators that
influence the functions and the migration of inflammatory cells
and by modifying the extracellular matrix homeostasis. Apart from
their role in acute airway inflammation, MMPs may contribute to
features of airway remodelling including reorganization of matrix,
angiogenesis and smooth muscle hyperplasia.
At ST, a decrease in mmu-miR-203 and -1 expression is
expected to induce the upregulation of MMP-24 and TIMP-3
(Figure 9). At IT, repression of mmu-miR-29b and -29c should
induce an increase expression of MMP-15 and -24 (Figure 4A-D)
but also of MMP-2. Moreover, these miRNAs can prospectively
target MMP-2 and MMP-15. Finally, at LT, TIMP-2 and TIMP-
Figure 4. Dose-response analysis of the effect of miR-29b, -29c and -146b on their predicted target in lung cells. Transient transfection
analysis for luciferase reporter expression with mouse Mmp-15 39UTR in the presence of miR-29b and -29c (Panel A); mouse Mmp-24 39UTR in the
presence and absence of miR-29b and -29c (Panel B); human Mmp-15 39UTR in the presence of miR-29b and -29c (Panel C); human Mmp-24 39UTR in
the presence of miR-29b and -29c (Panel D); mouse Col6a2 39UTR in the presence of miR-29c (Panel E); mouse Ctsk 39UTR in the presence of miR-29c
(Panel F); mouse Scube2 39UTR in the presence of miR-146b (Panel G); mouse Card10 39UTR in the presence of miR-146b (Panel H). Universal negative
siRNA was used at 20 nM as non-functional small RNA control. For each expression vector, the specific effect of the miRNA on luciferase acti-
vity was expressed as compared to the activity measured in the control condition, arbitrarily set at ‘‘100’’. Results are expressed as mean 6 SD.
(* p-value ,0.05; ** p-value ,0.001; # p-value ,0.005).
doi:10.1371/journal.pone.0016509.g004
Figure 5. Analysis of 13 miRNAs-predicted target murine genes in vitro. Transient transfection analysis for luciferase reporter expression with
Arid4b, Il-6 or Lpin2 39UTR in the presence of miR-223; with Gmnn, Nola2 or Ube2c 39UTR in the presence of miR-483; with Dera or Nusap1 39UTR in
the presence of miR-574-5p; with Cd3g or Phb2 39UTR in the presence of miR-672; and with Fst, Ctse or Cdca8 39UTR in the presence of miR-690.
Universal negative siRNA were used at 20 nM as non-functional small RNA control. For each expression vector, the specific effect of the miRNA on
luciferase activity was expressed as compared to the activity measured in the control condition, arbitrarily set at ‘‘100’’. Results are expressed as mean
6 SD. Each p-value is indicated in the graph.
doi:10.1371/journal.pone.0016509.g005
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(mmu-miR-30b, -30c, -30d, -21, -214 and -206).
Deregulation of TIMPs and MMPs activities can lead to an
exaggerated matrix turnover and be responsible for subepithelial
fibrosis observed in asthma. A common feature of MMP-15 and
MMP-24 is that they are membrane-type MMPs sharing an
identical substrate, the pro-MMP-2. In lung fibrosis, in the late
stages of the disease, MMP-2 may be associated to pathological
collagen deposition and interstitial fibrosis [89]. Since no
significant modifications in MMP-2, MMP-15 and MMP-24
mRNA levels were observed [4], it strongly suggests that miRNAs
regulate the translation of these MMPs [11]. This hypothesis is
further reinforced by our functional data showing that 39UTRs of
both human and mouse Mmp-15 and -24 are similarly targeted by
miR-29b and -29c. Finally these results are in line with those of
Henderson et al. [90] describing post-transcriptional regulation of
MMP-2 and TIMP-2 protein levels and demonstrating a sharp
increase in MMP-2 activation during airways remodelling in
asthma.
TIMPs are key regulators of the activity of many metallopro-
teinases including MMPs, ADAMs and ADAMTS. TIMP-1
mRNA upregulation during lung fibrosis has already been
described as TIMP-2 and TIMP-3 mRNA were shown to be
constitutively expressed [4,89]. TIMP-2 not only inhibits MMP-2
activity but is also involved in docking pro-MMP-2 to the cell
surface where the enzyme is activated [91] by membrane-bound
MMPs, including MMP-15 and MMP-24 [92], and by a second
molecule of TIMP-2. TIMP-3 binds to the extracellular matrix
Figure 6. Potential influence of miRNAs on immune response induced by OVA. In antigen presenting cells, MHC complexes are maturated
in endosomes by lysosomal reductases while CTSE processes antigen (Ag), i.e. OVA. Finally, the MHC/antigenic peptide complex translocates to the
plasma membrane and is presented to the TCR/CD3 complex on CD4+ T helper cell surface. Activation of TCR/CD3 induces the activation of NF-kB
through PKC activation and CARD11/BCL10/MALT1 complex recruitment. MiRNA modulation could occur through mmu-miR-690, -672 and -146b.
Cross-linking of costimulatory receptors on the T helper cell with corresponding ligands, such as TNFRSF9 with TNFSF9, also induces NF-kB and
regulators (MAPKs, JNK) of the activity of multiple transcription factors. Production of TNFSF9 could be under the control of mmu-miR-146b, thus
regulating the T helper cells properties. ST, IT, LT: short, intermediate and long-term treatments, respectively. The observed up- ( ) and down- ( )
regulations of the expression of some specific miRNAs are reported.
doi:10.1371/journal.pone.0016509.g006
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asthmatic airways [93]. At LT, 6 different miRNAs potentially
targeting TIMP-2 and TIMP-3 are significantly up or downreg-
ulated which is highly susceptible to affect the complex array of
interactions between MMPs and between MMPs and their targets
(extracellular matrix macromolecules, cytokines…) and may
represent a crucial regulatory switch during asthma disease.
Androgen Receptor Signalling Pathway. Several miRNAs
regulated in asthma target mRNAs that are implicated in the
Androgen Receptor Signalling Pathway (WP252). Although it
could seem surprising, cross-talk between this pathway and
regulatory cascades originating from growth factors (IGF1,
FGF2, EGF, TGFb) are well documented. In prostate and lung,
they have been shown to regulate several cell functions with direct
implication in chronic asthma (such as apoptosis, survival,
proliferation and differentiation [94,95]).
IGF1 is known to increase fibroblast survival and growth, and to
be an important mediator of inflammation and remodelling in the
asthmatic airways, as well as an inducer of bronchial smooth muscle
contraction [96,97]. We had previously shown that IGF1 mRNA is
strongly upregulated at ST, IT and LT [4]. This may be due to
transcriptional regulation [98] but possibly also to the repression of
miRNAs(mmu-miR-1atST;mmu-miR-450a-5patIT;mmu-miR-
27a and -92a at LT) that target IGF1 mRNA. Constant
upregulation of mmu-miR-146b could also influence changes that
occur in the complex IGF1-dependent regulatory cascades.
Figure 7. Regulatory pathways regulated by miRNAs as determined by the MicroCosm Targets algorithm. Fifty-one pathways were
identified at one time-point at least. While 28 pathways appeared to be modulated at only one stage of the disease (ST, IT or LT), 17 were regulated at
2 different time-points and 6 during the entire course of the disease. Stouffer’s method was used to identify significant enrichment for pathways
annotations among predicted targets of modulated miRNA in the model. ST, IT, LT: short, intermediate and long-term treatments, respectively.
doi:10.1371/journal.pone.0016509.g007
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between modulated miRNAs during mouse model of asthma and
transcription factors (SP1, POU2F2, PATZ1…), receptors (NRIP,
NR3C1…), nuclear receptor co-factors (NCOR2, NCOA1, NCOA3,
PIAS1, PIAS3, NROB1, PNRC1…) or signal transducers (IL6ST,
RAN…) participating in the Androgen Receptor Signalling Pathway.
These evidences support the hypothesis that, besides transcription
factors only, miRNA or miRNA/transcription factors networks
participate in the control of this pathway and of the release of IGF1.
Inflammatory Response Pathway. Recent reviews
[99,100] have shown evidence that miRNAs play a role in the
control of inflammation cascades and particularly in cytokines
regulation. Tumour necrosis factor-alpha (TNFa) promotes
inflammation and airway remodelling. It is intensely released in
asthmatic airways by pro-inflammatory cells, including activated
macrophages, but also by structural cells [101]. Its elevated levels
in asthmatic patients seem mainly due to a massive release of the
preformed cytokine [102] rather than to an increased
transcription. No correlation between miRNA modulation and
TNFa was made in this study. By contrast, the expression of its
two main receptors, TNFRSF1A (TNF-R1) and TNFRSF1B
(TNF-R2), is expected to be upregulated at ST and IT as a result
of the downregulation of mmu-miR-690, -805 and -574-5p (at ST)
and mmu-miR-29b, -29c, -152, -218 and 690 (at IT). This would
Figure 8. Regulatory pathways regulated by miRNAs as determined by the TargetScan algorithm. Fifty-three pathways were identified
at one time-point at least. While 30 pathways appeared to be modulated at only one stage of the disease (ST, IT or LT), 18 were regulated at 2
different time-points and 5 during the entire study. Stouffer’s method was used to identify significant enrichment for pathways annotations among
predicted targets of modulated miRNA in the model. ST, IT, LT: short, intermediate and long-term treatments, respectively.
doi:10.1371/journal.pone.0016509.g008
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surface, and could contribute to an amplification of this regulatory
cascade, in synergy with the massive release of TNFa. At LT,
mmu-miR-29c and -98 are downregulated but upregulation of
mmu-miR-125b-5p and -574-5p, and progressive normalization of
the levels of mmu-miR-218, -690 and -805 would then be part of
the reduction of the inflammatory process at the late stage of the
asthma model through the modulation of TNFa receptors.
Downregulation of mmu-miR-29 members is strongly correlat-
ed with Inflammatory Response Pathway (WP458) especially with
the extracellular matrix components directly involved in fibrosing
processes. These miRNAs are speculated to regulate the
expression of type I and type III collagens but also the laminin c
chain LAMC1. Evidence that miR-29b attenuates expression of
collagen genes by blocking their mRNA translation has already
been described [103,104] and an inverse correlation between the
expression of mmu-miR-29b and -29c and the synthesis of
collagen type I and III is further evidenced here. This suggests
that downregulation of mmu-miR-29 members coud be one of the
causes of the subepithelial fibrosis observed in chronic asthma.
Fibronectin (FN1) is present in large quantities in fibrosing areas
[105], precedes collagen type I deposition and is necessary for
pulmonary fibrosis to develop [106]. Surprisingly however, its
mRNA is only slightly upregulated at IT and not at ST or LT [4].
This apparent discrepancy can probably be explained by the
decrease of the post-transcriptional repression by miRNAs at each
step of the progression of the disease [107-109]. Here we showed
that several modulated miRNAs could potentially target Fn1
mRNA at the three time-points. All of them were downregulated:
mmu-miR-1 and -805 at ST, mmu-miR-199a-3p, -200a and -429
at IT and mmu-miR-27a and -200b at LT, except mmu-miR-206
which was upregulated at LT.
Together with collagens and fibronectin, laminin is another key
component of the extracellular matrix that is exceedingly
accumulated in airway walls during remodelling processes in
patients with severe bronchial asthma [110]. In this mouse model
of asthma, various laminin chains (LAMA5, LAMB1, LAMC1 and
LAMC2) expressions were predicted to be affected by many
miRNAs. However, there is no clear tendency at ST and LT where
targeting miRNAs are up- or downregulated in equal proportions.
At IT, expressions of mmu-miR-29b, -29c, -152, -200a and -690
that potentially target laminin c chain LAMC1 are inhibited.
The miRNAs implication in the regulation of the Inflammatory
Response Pathway appears to occur principally through the
Figure 9. miRNAs and MMP-2 activation. Panel A represents MMP-14 (MT1-MMP)-dependent activation pathway for MMP-2. TIMP-2 activates
pro-MMP-2 by forming a complex that interacts with the MMP-14/TIMP-2 complex at the cell membrane. Activation of pro-MMP-2 occurs in a two
step process: cleavage within the MMP-2 prodomain followed by an autocatalytic cleavage which results in the active 62 kD form. Panel B represents
the presumed MMP-15 (MT2-MMP) and MMP-24 (MT5-MMP)-dependent activation pathway for MMP-2. Activation of pro-MMP-2 occurs in a two step
process: cleavage within the MMP-2 prodomain in the absence of TIMP-2 followed by a second cleavage, enhanced by an unidentified secreted
soluble protein which results in the active 62 kD form. The mechanism by which MMP-24 releases active MMP-2 is currently unknown. The intensive
activation of MMP-2 contributes to collagen deposition and interstitial fibrosis. An excess of TIMP-2 and the extracellular matrix-anchored TIMP-3
contribute, respectively, to the degradation of pro-MMP-2 and to the inhibition of MMP-2. ST, IT, LT: short, intermediate and long-term treatments,
respectively. The observed up- ( ) and down- ( ) regulations of the expression of some specific miRNA are reported.
doi:10.1371/journal.pone.0016509.g009
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than through the modulation of cytokines and their receptors,
except for the TNF-a receptors.
IL-3 Signalling Pathway. In silico analysis predicted IL-3
Signalling Pathway (WP373) as regulated by miRNAs. Eosinophils
activated by IL-3 contribute to T cell activation in allergic diseases
[111] and play a critical role in the induction of airway
hyperreactivity and the development of lesions that underpin
chronic airway wall remodelling [112].
IL-3 induces transient association between paxillin (PXN) and
vinculin (VCL), two cytoskeletal proteins necessary for the
contractile response of smooth muscle cells as observed during
asthma [113]. During the whole time course of the model, PXN is
a potential target of several downregulated (mmu-miR-203, -218,
-30b, -30c, -27a and -21) and upregulated (mmu-miR-20b, -466g,
-30d and -145) miRNAs. At IT and LT, VCL is a potential target
of 5 downregulated miRNAs (mmu-miR-21, -25, -29b, -29c and
-92a). Besides VCL binding, PXN interacts with SRC and CRK
family members [114], which leads to proliferation and differen-
tiation processes in fibroblasts through the MAPK pathway or
regulates the formation of physical links between the cytoskeleton
and integrin proteins that mediate transmission of contraction
forces [115]. It is of interest that a large number of modulated
miRNAs were pointed out to interact with SRC (mmu-miR-197
and -230), CRK and CRKL (mmu-miR-203, -497, -218, -320,
-214, -328), and various MAPKs (4 miRNAs for MAPK1, 3, 8 and
14; 7 miRNAs for MAPK9; 13 miRNAs for MAPK7; see Tables
S5-S10 for details).
IL-3 induces Toll-like receptors expression in dendritic cells
[116] that then initiate the activation of T lymphocytes for specific
antigens [117]. Genes implicated in Toll-like receptors signaling
such as GSK3B (a glycogen synthase kinase), SOCS3 (a suppressor
of cytokine signalling-3) and ATF2 (an activating transcription
factor) were defined as targets of modulated miRNAs during all
time-course of the mouse model of asthma, respectively mmu-
miR-23a, -23b, -26b, -29b, -29c, -155 and -214 for Gsk3b; mmu-
miR30b, -30c, -30d, -152, -203, -207, -218 and -455 for Atf2;
mmu-miR30b, -30c, -30d, -152, -203, -207, -218 and -455 for
Socs3.
YWHA proteins (tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein) act as adaptor proteins in
cellular signaling and metabolism by regulating and coordinating a
diverse array of cellular processes, such as cell cycle progression,
apoptosis, protein trafficking, cytoskeleton rearrangements, me-
tabolism, and transcriptional regulation of gene expression [118].
They can bind to GSK3 [119], implicated in Toll-like receptors
Figure 10. Experimental protocol. Sensitization and short-term (ST), intermediate-term (IT) and long-term (LT) PBS/ovalbumin (OVA) exposure
protocols. BALB/c male mice were sensitized on days 1 and 7 (ST) or 11 (IT and LT) by intraperitoneal injection of 10 mg OVA. At day 22, mice were
subsequently exposed to PBS or OVA 1% aerosol for 30 min per day. For ST, aerosol challenge was performed for 7 consecutive days (grey box). For IT
or LT, aerosol challenges were performed three or five times (black boxes) according to a pattern of 5-day inhalation (black boxes) followed by a
9-day time off (white boxes). Mice were sacrificed the day after last aerosol challenge.
doi:10.1371/journal.pone.0016509.g010
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Tables S5-S10 for details) could target mRNAs of three members
of YWHA protein family: Ywhab, Ywhaq and Ywhaz. To our
knowledge, the role of these proteins in asthma is not known.
The whole analysis for each time-point, including details on
number of miRNA and miRNA-mRNA interactions in specific
pathways is available in online supplemental data.
In conclusion, this work represents the first large scale study
aiming at evaluating the implication of miRNAs during asthma,
from early inflammation to chronically remodelled airways.
Highly significant correlations between regulation of miRNAs
expression and several biological processes or regulatory pathways
have been found at each step of the evolution of allergen-induced
asthma in mice. Similar results were obtained by comparing our
data with two different databases using different computational
analyses, further reinforcing the significance of this study.
Although direct confirmation of the specific implication in vivo of
the most promising miRNA-mRNA pairs have yet to be
performed, the miRNAs profiling data described in the present
work are new information allowing a better understanding of
molecular mechanisms participating in this complex and progres-
sive pathology and might lead to novel therapeutic approaches
targeting either some specific miRNAs of the regulatory processes
identified here.
Methods
Mouse model of asthma
BALB/c mice were used following ‘‘Principles of Laboratory
Animal Care’’ formulated by the National Society for Medical
Research, and the experimental protocols were approved by the
local animal ethical committee (University of Lie `ge) under the
no. 03/158. Six- to 8-week old BALB/c male mice were sensitized
on days 1 and 7 or 11 (see below) by intraperitoneal injection of
10 mg of ovalbumin (OVA Grade III; Sigma-Aldrich, Schnelldorf,
Germany) emulsified in aluminum hydroxide (AlumInject; Perbio,
Erembodegem, Belgium). Animals were subsequently divided into
2 groups of six animals: 1 group of control mice was exposed to
phosphate buffer saline (PBS) aerosol and the other experimental
group was subjected to ovalbumin (OVA) aerosol 1% aerosol for
30 min. A three time-points, named ‘‘short-term’’ (ST), ‘‘interme-
diate-term’’ (IT) and ‘‘long-term’’ (LT), exposure protocol was
designed to reproduce the airway hyperresponsiveness, the
inflammation phase and the remodelling process observed during
the course of asthma development. At day 21, aerosols were
generated daily by ultrasonic nebulizer (DeVilbiss 2000) and
performed for 7 consecutive days (ST protocol). For IT or LT
protocols, aerosols were performed three (IT) or five (LT) times
according to a pattern of 5-day inhalation followed by a 9-day time
off. After determination of airway reactivity, mice were sacrificed
by cervical dislocation the day after last aerosol challenge. The
experimental protocols are illustrated in Figure 10.
Lung tissue processing and RNA extraction
For each time-point experiment (ST, IT or LT), PBS-treated
(n=6) and OVA-treated (n=6) mice were killed by cervical
dislocation. Further to lung eosinophilia, differential cell counts
were performed in bronchoalveolar lavages (BAL) in PBS- and
OVA-treated mice. After sacrifice of mice, a cannula was placed in
the trachea and a BAL was performed by gentle manual
instillation and aspiration using 461 ml of 0.05 mM cold PBS-
EDTA (Calbiochem, Germany). The BAL was centrifuged (250 g,
10 min, 4uC). The cell pellet was resuspended in 1 ml of PBS-
EDTA. Total cells counts were obtained using a hemocytometer.
The differential cell counts were performed using morphological
criteria on cytocentrifuged preparations (Cytospin) after staining
with Diff-Quick (Dade, Belgium). Differential cell counts were
performed by one observer unaware of the various experimental
conditions.
Immediately after BAL, the right lobe of the lung was stored in
liquid nitrogen. The left lobe was used for histological assessment
of airway remodeling histology as previously described [4].
Tissue disruption was performed with a Mikro-Dismembrator
in liquid nitrogen and tissue powder (50 to 100 mg) was directly
homogeneized in 1 ml of Trizol reagent. Phase separation was
performed according to reagent protocol. Total RNA was
precipitated by an overnight incubation in 0.5 ml of isopropanol
at 280uC. Centrifugation (12,000 g, 10 min, 4uC) was then
performed and RNA pellet was washed twice by ethanol 75% and
centrifugation (7,500 g, 5 min, 4uC). Total RNA pellet was briefly
air-dried in a sterile hood, finally dissolved in RNase free water
(50 to 100 ml) and stored at 280uC.
RNA quality control
Each total RNA sample concentration was determined using a
NanoDrop ND-1000 spectrophotometer. The integrity of each
total RNA extract was assessed with an Agilent 2100 Bioanalyzer
and degraded samples were rejected. The passing criteria for use
in miRNA microarray and quantitative real-time PCR was a 28S/
18S rRNA ratio between 0.90 and 1.80 (maximum obtained). The
presence of small RNA was evidenced by a clear peak at about 25
seconds.
miRNA microarray analysis
Microarray assay was performed using a service provider (LC
Sciences, Houston, Texas). The assay started with 5 mg total RNA
pools containing equal amount of RNA from individual lung (n=6
per pool), which was size-fractionated using a YM-100 Microcon
centrifugal filter (Millipore, Billerica, MA), and the isolated small
RNAs (,300 nt) were 39-extended with a poly(A) tail using poly(A)
polymerase. An oligonucleotide tag was then ligated to the poly(A)
tail for later fluorescent dye staining (Cy3 and Cy5 were used for
the two RNA pools, OVA versus PBS for each time-point, in a
duplicate experiment). Hybridization was performed overnight on
a mParaflo microfluidic chip using a microcirculation pump
(Atactic Technologies, Houston, TX) [120]. On the microfluidic
chip, each detection probe consisted of a chemically modified
nucleotide coding a segment complementary to target microRNA
(with mice probe content from miRBase, version 10.0, http://
microrna.sanger.ac.uk/sequences/) or other control RNA, and a
spacer segment of polyethylene glycol to extend the coding
segment away from the substrate. The detection probes were made
by in situ synthesis using photogenerated reagent chemistry.
Hybridization used 100 ml6 6 SSPE buffer (0.90 M NaCl,
60 mM Na2HPO4, 6 mM EDTA, pH 6.8) containing 25%
formamide at 34uC. After RNA hybridization, tag-conjugating
Cy3 or Cy5 dyes were circulated through the microfluidic chip for
dye staining. Fluorescence images were collected using a laser
scanner (GenePix 4000B, Molecular Devices, Sunnyvale, CA) and
digitized using Array-Pro image analysis software (Media Cyber-
netics, Bethesda, MD). Data were analyzed by first substracting
the background and then normalizing with a cyclic LOWESS
filter (Locally-weighted Regression) [121]. For two color experi-
ments (OVA versus PBS pools for each time-point), the ratio (log
transformed) of the two sets of detected signals, and p-values of the
t-test, were calculated. Differentially detected signals was accepted
as true when the ratios of the p-value was less than 0.01. Results
were finally given in terms of ‘‘fold induction’’.
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In order to reassess the reproducibility of our mouse model
asthma and to use in this study the previously described
transcriptomic data [4], the expression of 8 genes regulated at
least at one time-point was measured for each individual mouse.
Total RNA (1 mg) was reverse transcribed using random primers
(Eurogentec, Belgium) and SuperScript III Reverse Transcriptase
(Invitrogen) according to manufacturer’s protocol. cDNAs were
then subjected to real time PCR using SYBR Green qPCR
Mastermix buffer (Eurogentec, Belgium). Primers used to amplify
Ccl8, Fcgr2b, Chia, Birc5, Cdc2a, Pon1, Arg1 and Mmp-12
have been previously described [4]. Expression levels of
each mRNA were evaluated using comparative threshold cycle
(Ct) method, normalized to those of b2-microglobulin and
hypoxanthine guanine phosphoribosyl transferase 1 (house-
keeping genes) for each condition (delta Ct). Experiments
were done at least in duplicate. The fold change of each
mRNA was calculated as a difference between mean values
obtained for OVA- and PBS-treated mice at each time-point (delta
delta Ct). The fold difference in expression was calculated using
the 2
-delta delta Ct method. Mean values of fold difference for each
cohort used here were compared to those obtained previously [4]
(Figure S1).
In order to validate miRNA microarray analysis and to evaluate
inter-individual variation in each group of mice, real-time
quantitative RT-PCR assays (QuantiMir RT Kit Small RNA
Quantitation System, SBI System Biosciences, USA) were on
individual lung RNA sample to confirm the differential expression
of 14 miRNAs. The selection of the miRNAs is based on their
potential role in the pathology of the lung (mmu-miR-1, 146b, -
203, -21, -223, -29b, -29c) or on their high and significant
differential expression in the model (mmu-miR-455, -574-5p, -
672, -690) or for their high (mmu-let-7b a, mmu-miR-145) or low
(mmu-miR-450a-5p) signal intensity in microarray analysis. The
protocol is based on poly(A) tailing and reverse transcription of
small non-coding RNAs to provide cDNA synthesis of miRNA. A
universal 39-tag sequence is incorporated during reverse transcrip-
tion to enable miRNA expression analysis by quantitative PCR.
The reverse sense primer is universal and provided by the kit. The
forward sense primer is designed by using the sequence of the
mature miRNA (59-19 nucleotides) converted in DNA sequence
(Table 6). Forward LNA primers (Exiqon, Denmark) were used to
amplify mmu-miR-146b, -29b and 29c in order to increase
specificity and discrimination that were not obtained with native
DNA primers. Reactions are performed following manufacturer’s
protocol with 2 mg of total RNA and SYBR Green qPCR
Mastermix buffer (Eurogentec, Belgium). Expression levels of each
mature miRNA were evaluated using comparative threshold cycle
(Ct) method, normalized to those of U6 small nuclear RNA
(house-keeping gene) for each condition (delta Ct). The fold
change (OVA-PBS means) of each miRNA was calculated and
expressed as 2
2delta delta Ct. Mean values of fold difference for each
cohort were compared to mean values obtained for pools analyzed
by microarray hybridization.
mRNA microarray analysis
Microarray raw mRNA expression data were from [4] and are in
full agreement with RT-qPCR data obtained in this study for new
cohort of mice. Probe-level data was background-adjusted and
normalized, and gene expression measurements were obtained with
the robust multi-array average (RMA) method [122], as imple-
mented in the Affy package of Bioconductor. For each of the three
time points, the gene expression log ratios were computed between
the PBS control and from two different OVA-treated pools. Genes
with a mean OVA/PBS log ratio more than 0.6 or less than 20.6
were selected as up-regulated or down-regulated, respectively.
These values correspond to genes regulated 1.52-fold up or down.
When more than one expression value was present for a gene
(multiple probe sets per gene), the gene was considered up- or
down-regulated if the direction of change (up/down) was
consistent between all probe sets, and at least one of the probe
sets satisfied the -0.6/0.6 threshold on log ratios.
miRNA-mRNA correlation analysis
Potential correlations between miRNAs and mRNAs regulated
at each time-point were determined by crossing the lists of
modulated mRNAs and miRNAs with a database of miRNA
target predictions. The list of candidates mRNA targets for each
miRNA was retrieved from the MicroCosm Targets database
Version 5 (http://www.ebi.ac.uk/enright-srv/microcosm), for-
mely known as mirBase::Targets [12], that uses the miRanda
algorithm [123] to identify potential binding sites for a given
miRNA in gene sequences. All modulated miRNAs were
represented in this database.
Fifteen modulated genes (among 1955 in total) were not
predicted as targets of any miRNAs.
Table 6. Mature miRNA sequences and forward primers sequences for real-time quantitative PCR.
MIRNA MIRBASE # MIRNA SEQUENCE FORWARD PRIMER SEQUENCE
mmu-let-7b MIMAT0000522 59 - ugagguaguagguugugugguu – 39 59 - tgaggtagtaggttgtgtg – 39
mmu-miR-1 MIMAT0000123 59 - uggaauguaaagaaguauguau - 39 59 - tggaatgtaaagaagtatg - 39
mmu-miR-145 MIMAT0000157 59 - guccaguuuucccaggaaucccu - 39 59 - gtccagttttcccaggaat - 39
mmu-miR-203 MIMAT0000236 59 - gugaaauguuuaggaccacuag - 39 59 - gtgaaatgtttaggaccac - 39
mmu-miR-21 MIMAT0000530 59 - uagcuuaucagacugauguuga - 39 59 - tagcttatcagactgatgt - 39
mmu-miR-223 MIMAT0000665 59 - ugucaguuugucaaauacccca - 39 59 - tgtcagtttgtcaaatacc - 39
mmu-miR-450a-5p MIMAT0001546 59 - uuuugcgauguguuccuaauau - 39 59 - ttttgcgatgtgttcctaa - 39
mmu-miR-455 MIMAT0003742 59 - gcaguccacgggcauauacac - 39 59 - gcagtccacgggcatatac - 39
mmu-miR-574-5p MIMAT0004893 59 - ugagugugugugugugagugugu - 39 59 - tgagtgtgtgtgtgtgagt – 39
mmu-miR-672 MIMAT0003735 59 - ugagguugguguacuguguguga - 39 59 - tgaggttggtgtactgtgt - 39
mmu-miR-690 MIMAT0003469 59 - aaaggcuaggcucacaaccaaa - 39 59 - aaaggctaggctcacaacc - 39
doi:10.1371/journal.pone.0016509.t006
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such that the mRNA is predicted as a potential target of the
miRNA and the miRNA and the mRNA are differentially
expressed in opposite direction, i.e. the miRNA is down-regulated
and the mRNA is up-regulated, or the opposite. Tables S2, S3,
and S4 list all these pairs respectively at ST, IT and LT. The
p-values in these tables are the p-values associated with the target
prediction as described in [124] (only targets with a p-value lower
than 0.05 are included in the MicroCosm Targets database).
Pathway analysis
A pathway enrichment analysis was carried out taking into
account both modulated miRNAs and mRNAs. A list of 117
pathways was downloaded from WikiPathways (http://www.
wikipathways.org, [125]). Predicted candidates mRNA targets for
each differentially expressed miRNA were identified using two
databases: MicroCosm Targets Version 5 (http://www.ebi.ac.uk/
enright-srv/microcosm) and TargetScan Version 4.2 (http://
www.targetscan.org).
For each pathway and each time-point, a p-value reflecting the
enrichment of the pathway in modulated miRNA targets (with at
least 1.5-fold, up or down) was computed as follows: we counted
the total number of miRNA-gene pairs such that the miRNA is
modulated, the gene belongs to the pathway and is a potential
target of the miRNA. A p-value was then associated to this number
by computing the proportion of times (estimated from 1000 trials)
a purely random selection of the modulated miRNAs (among the
566 miRNAs on the chip) gives a number of pairs as high as the
Table 7. Genes, species and their amplified 39UTRs with corresponding primers.
Gene Species 3’UTR size* Forward Primer Reverse Primer
Arid4b M. musculus 2385 GCCGTGTAATTCTAGA-
acaacaaaaagaagggaaaagg
GTCTGCTCGAAGCGG-
gaatttacggtttgatttggtg
Card10 M. musculus 1727 GCCGTGTAATTCTAGA-
ggaggtgactgagaagaatgtcc
GTCTGCTCGAAGCGG-
tctatgacaaactttaatgactcattg
Cd3g M. musculus 603 GCCGTGTAATTCTAGA-
tgtgaaaactgcattgagctaaa
GTCTGCTCGAAGCGG-
taggttatacttgatcttttaattttgtca
Cdca8 M. musculus 786 GCCGTGTAATTCTAGA-
ctcccgggtcttcaagact
GTCTGCTCGAAGCGG-
gacttaaaaccatggcaaactaaga
Col6a2 M. musculus 849 GCCGTGTAATTCTAGA-
tggccttcccactgaccta
GTCTGCTCGAAGCGG-
aacagggaggctcaaaacct
Ctse M. musculus 980 GCCGTGTAATTCTAGA-
tgccctggatggaatcc
GTCTGCTCGAAGCGG-
gatatttaaaatcaaatcagtttatgggtt
Ctsk M. musculus 759 GCCGTGTAATTCTAGA-
agaggttctaggggcagcc
GTCTGCTCGAAGCGG-
ttgtaaatgagatactttatttcaaataca
Dera M. musculus 848 GCCGTGTAATTCTAGA-
cctggtcaaggaggaactagg
GTCTGCTCGAAGCGG-
atttaaaaattcagcgatatccaca
Fst M. musculus 1410 GCCGTGTAATTCTAGA-
aaaaaatgcctatgggattcc
GTCTGCTCGAAGCGG-
tcactcatcatttatctacaaatacacatt
Gmnn M. musculus 980 GCCGTGTAATTCTAGA-
gcgcgtcagctaccg
GTCTGCTCGAAGCGG-
ttttacaatgttcaacaggaaattg
Il6 M. musculus 1090 GCCGTGTAATTCTAGA-
ccaagaacgatagtcaattccag
GTCTGCTCGAAGCGG-
aaatataatataatttatttgtttgaagacagtctaa
Lpin2 M. musculus 3069 GCCGTGTAATTCTAGA-
cagactgtaggatatttactgtgaatcc
GTCTGCTCGAAGCGG-
ttatcagtttatgttagtttattattgtaacattt
Mmp-15 M. musculus 1772 GCCGTGTAATTCTAGA-
gcagcccagaaccctctc
GTCTGCTCGAAGCGG-
aacactgtatttctgttttatttagaaatgat
Mmp-15 H. sapiens 1439 GCCGTGTAATTCTAGA-
taacggtgctcaggggg
GTCTGCTCGAAGCGG-
tttgccggctgtacaattta
Mmp-24 H. sapiens 2353 GCCGTGTAATTCTAGA-
caggcccttcctcacca
GTCTGCTCGAAGCGG-
cactctgtatttctgttttatttagaaa
Mmp-24 M. musculus 2318 GCCGTGTAATTCTAGA-
caggtagcacccgcagc
GTCTGCTCGAAGCGG-
gcaggttccagtgcattttatt
Nola2 M. musculus 1004 GCCGTGTAATTCTAGA-
ggccgcgtggttcct
GTCTGCTCGAAGCGG-
gttttataactttgagcaaatatattcatag
Nusap1 M. musculus 1400 GCCGTGTAATTCTAGA-
cctcaactacaagccacacaaa
GTCTGCTCGAAGCGG-
gctaccacattcagcttagcttt
Phb2 M. musculus 640 GCCGTGTAATTCTAGA-
agagtacacagctgctgtagaagc
GTCTGCTCGAAGCGG-
ggctttaagtaataaaaattttattgagaa
Scube2 M. musculus 836 GCCGTGTAATTCTAGA-
attcagttcaagtccaatgaagg
GTCTGCTCGAAGCGG-
tttaatcatcactgtttagaactcacac
Ube2c M. musculus 931 GCCGTGTAATTCTAGA-
gcagttgccctttcctctc
GTCTGCTCGAAGCGG-
acaaaacaatcaatgtgtatttatttaat
*Size (bp) of amplified 39UTRs for each target.
doi:10.1371/journal.pone.0016509.t007
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modulated mRNAs was computed from the number of modulated
genes in the pathway using the hypergeometric distribution (using
the set of 20461 genes of the chip as a reference set). For this
analysis, the set of modulated genes was defined as the set of genes
with a fold induction greater than 1.5 in both experiments. A
unique p-value was finally associated to each pathway by
combining the miRNA and mRNA p-values using Stouffer’s
method [126].
Functional validation
Cell Culture and Reagents. SV40-transformed human lung
fibroblasts WI26 were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen) supplemented with 10% FBS
(Lonza). All cells were incubated at 37uC in a humidified
chamber supplemented with 5% CO2.
Plasmid constructs. The luciferase-UTR reporter plasmids
were constructed by introducing 39UTR of 21 genes carrying
putative miRNA binding sites into pGL3-promoter vector that
contains an SV40 promoter upstream of the luciferase gene
(#E1761, Promega). 39UTR sequences were amplified from WI26
cDNA (for human 39UTRs) and from total lung Balb/c mice
cDNA (for murine 39UTRs) by PCR (see Table 7 for amplified
39UTRs and primers) using the Easy-AH One-Tube RT-PCR
System (#600182, Agilent Technologies-Stratagene Products).
After double digestion by FseI and XbaI of the pGL3-promoter
vector (#E1761, Promega), the 39UTRs were cloned into this
vector using the In-Fusion cloning kit (#639619, ClonTech). The
correct insertion of these 39UTRs into the pGL3-promoter vector
was verified by restriction analysis and sequencing.
Transfection. WI26 cells were transfected using jetPRIME
reagent (Polyplus transfection) following the manufacturer’s protocol
for DNA and miRNA mimic cotransfection. In brief, 60 000 cells
were seeded in a 24-well plate 24 hours prior transfection. They were
transfected on the following day with 250 ng of plasmid DNA and
w i t h2 . 5t o3 0n Mm i R N Am i m i c( m i S c r i p tm i R N AM i m i c ,Q i a g e n )
(Table 8) or 20 nM AllStars Negative Control siRNA (Qiagen) per
well. Transfection medium was then replaced by cell growth medium
24 hours after transfection.
Luciferase Assay. Luciferase assays were carried out in
WI26 cells 40 hours after transfection as a way to determine the
effect of microRNAs on the activity of Luc-39UTRs. Cells were
harvested, lysed and luciferase activity was determined by using
Luciferase Reporter Gene Assay, high sensitivity (Roche Applied
Science, Belgium) according to the manufacturer’s protocol.
Protein quantification was used for normalization. Knockdown
was calculated as a ratio comparing for each construct the
luciferase activity measured in presence of the specific miRNA to
the activity obtained in presence of the non-functional control.
Experiments were done at least in duplicate and data are
presented as means 6 SD. Statistical analyses were performed
using unpaired two-tailed Student’s t-tests.
Supporting Information
Figure S1 mRNA expression profiles in our models of
allergen-induced asthma. Validation of reproducibility of our
models of allergen-induced asthma was assessed by comparing the
mRNA level of a series of selected genes measured by RT-qPCR
(in duplicate) on individual lung RNA in each group (ST, IT LT)
of PBS- and OVA-treated mice to data obtained by microarray
analysis in a previous study [4]. The graphs illustrate a
concordance of 8 significantly modulated genes. mRNA levels
were normalized by using b2-microglobulin and hypoxanthine
guanine phosphoribosyl transferase transcripts. Differences (fold
induction) between samples (OVA vs PBS) were calculated using
the 2
-delta delta Ct method. Results are expressed as mean 6 SD.
(TIF)
Table S1 Significantly modulated mature miRNAs and their
respective fold induction for each time-point experiment.
(DOC)
Table S2 Modulated mRNAs and inversely correlated modu-
lated miRNAs at ST using MicroCosm Targets.
(DOC)
Table S3 Modulated mRNAs and inversely correlated modu-
lated miRNAs at IT using MicroCosm Targets.
(DOC)
Table S4 Modulated mRNAs and inversely correlated modu-
lated miRNAs at using MicroCosm Targets.
(DOC)
Table S5 MiRNAs/mRNAs regulatory pathways at ST using
MicroCosm Targets.
(DOC)
Table S6 MiRNAs/mRNAs regulatory pathways at IT using
MicroCosm Targets.
(DOC)
Table S7 MiRNAs/mRNAs regulatory pathways at LT using
MicroCosm Targets.
(DOC)
Table 8. Targeted 39UTR sequences, corresponding miRNA
Mimic and concentrations used.
GENE MISCRIPT MIRNA MIMIC CONCENTRATIONS
Arid4b Syn-hsa-miR-223 20 nM
Card10 Syn-hsa-miR-146b 2.5, 5, 10, 20, 30 nM
Cd3g Syn-hsa-miR-672 20 nM
Cdca8 Syn-hsa-miR-690 20 nM
Col6a2 Syn-hsa-miR-29c 2.5, 5, 10, 20, 30 nM
Ctse Syn-hsa-miR-690 20 nM
Ctsk Syn-hsa-miR-29c 2.5, 5, 10, 20, 30 nM
Dera Syn-hsa-miR-574-5p 20 nM
Fst Syn-hsa-miR-690 20 nM
Gmnn Syn-hsa-miR-483 20 nM
Il6 Syn-hsa-miR-223 20 nM
Lpin2 Syn-hsa-miR-223 20 nM
Mmp-15 (m, h) Syn-hsa-miR-29b,
Syn-hsa-miR-29c
2.5, 5, 10, 20, 30 nM
Mmp-24 (m, h) Syn-hsa-miR-29b,
Syn-hsa-miR-29c
2.5, 5, 10, 20, 30 nM
Nola2 Syn-hsa-miR-483 20 nM
Nusap1 Syn-hsa-miR-574-5p 20 nM
Phb2 Syn-hsa-miR-672 20 nM
Scube2 Syn-hsa-miR-146b 2.5, 5, 10, 20, 30 nM
Ube2c Syn-hsa-miR-483 20 nM
(m, h): murine and human 39UTRs.
doi:10.1371/journal.pone.0016509.t008
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of asthma at ST using TargetScan.
(DOC)
Table S9 MiRNAs/mRNAs regulatory pathways at IT using
TargetScan.
(DOC)
Table S10 MiRNAs/mRNAs regulatory pathways at LT using
TargetScan.
(DOC)
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